C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) has announced its anticipated milestones for 2025, highlighting the company's progress in developing targeted protein degradation therapies for oncology. The company is focused on advancing its clinical-stage programs and leveraging its TORPEDO® platform to create orally bioavailable degraders for various cancer targets.
Cemsidomide: Advancing in Multiple Myeloma and Non-Hodgkin’s Lymphoma
Cemsidomide, an oral degrader of IKZF1/3, is being developed for relapsed/refractory multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Data presented at the American Society of Hematology (ASH) Annual Meeting supported a potentially best-in-class profile for cemsidomide. The company plans to:
- Initiate the next phase of clinical development to investigate cemsidomide in combination with dexamethasone in late-line MM, and with other MM agents for earlier lines of treatment, expected in early 2026.
- Complete Phase 1 dose escalation and present data in the second half of 2025 for both MM and NHL.
- Open expansion cohorts in the Phase 1/2 trial for patients with peripheral T-cell lymphoma (PTCL) in the second half of 2025.
- Enable initiation of the next phase of clinical development to investigate cemsidomide monotherapy in later lines of therapy in PTCL, anticipated in early 2026.
Data from the ASH meeting showed that cemsidomide, in combination with dexamethasone, achieved an overall response rate (ORR) of 36% at the 75 μg once daily (QD) dose level. As a monotherapy, cemsidomide demonstrated a 38% ORR across all NHL subtypes and doses, with a 44% ORR and a 25% complete metabolic response rate in PTCL.
CFT1946: Targeting BRAF V600 Mutations in Solid Tumors
CFT1946 is an oral degrader targeting BRAF V600 mutations for solid tumors, including colorectal cancer (CRC) and melanoma. C4T plans to:
- Complete monotherapy Phase 1 dose escalation in BRAF V600 mutant solid tumors in the first half of 2025.
- Generate data from Phase 1 cohorts exploring CFT1946 monotherapy in melanoma, in combination with cetuximab in CRC, and in combination with trametinib in melanoma. These data will inform the next phase of development.
- Present Phase 1 data in the second half of 2025, including monotherapy in BRAF V600 mutant solid tumors, monotherapy expansion cohorts in melanoma, and in combination with cetuximab in CRC.
Previous data presented at the European Society of Medical Oncology (ESMO) Congress showed that CFT1946 was well-tolerated and demonstrated initial signs of anti-tumor activity. Preclinical data also indicated that CFT1946 can cross the blood-brain barrier, with Kpu,u values ranging from 0.34 to 0.88.
CFT8919: Addressing EGFR L858R-Mutated Non-Small Cell Lung Cancer
CFT8919 is an oral degrader targeting EGFR with the L858R mutation for non-small cell lung cancer (NSCLC). C4T's partner, Betta Pharmaceuticals, is leading a Phase 1 dose escalation study in Greater China. Data from this study will be used to determine the next phase of development for CFT8919 outside of China.
Discovery and Financial Outlook
C4T will continue to use its TORPEDO® platform to develop orally bioavailable degraders for oncology and non-oncology targets. The company plans to present and publish preclinical work and advance internal and collaboration programs to key milestones.
C4T expects its cash, cash equivalents, and marketable securities as of December 31, 2024, along with anticipated collaboration expense reimbursements, to fund operations into 2027.
